MedTrace Logo

Vellore Typhoid Vaccine Impact Trial

NCT05500482 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 72400

Last updated 2026-03-17

No results posted yet for this study

Summary

This cluster randomised trial will examine the impact of introducing TyphiBEV, a typhoid conjugate vaccine licensed in India, on the incidence of typhoid fever in a high burden urban setting in South India.

Conditions

  • Typhoid Fever

Interventions

BIOLOGICAL

Typhoid conjugate Vaccine

TyphiBEV is a clear colourless monovalent vaccine containing 25 µg of Typhoid Vi polysaccharide manufactured using the Citrobacter freundii sensu lato3056 (Vi) and is conjugated to CRM 197 as a carrier protein. Sodium chloride and Phosphate buffer are used as a buffering agent in the vaccine formulation with 2-Phenoxyethanol as a preservative.

Sponsors & Collaborators

  • Bill and Melinda Gates Foundation

    collaborator OTHER

  • University College, London

    collaborator OTHER

  • Imperial College London

    collaborator OTHER

  • Christian Medical College, Vellore, India

    lead OTHER

Principal Investigators

  • Jacob John, MD PhD · Christian Medical College, Vellore, India

  • Gagandeep Kang, MD PhD · Christian Medical College, Vellore, India

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-01
Primary Completion
2026-01-31
Completion
2026-02-28

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05500482 on ClinicalTrials.gov